Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!
LIU Yayi, ZHANG Junping. Research progress of cryptotanshinone on anti-fibrosis and its mechanism[J]. Journal of Pharmaceutical Practice and Service, 2023, 41(3): 146-148, 186. doi: 10.12206/j.issn.2097-2024.202208061
Citation:
FANG Huiyu, GU Yanying. Effects of ziprasidone on serum cholinesterase concentration in schizophrenia patients[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 88-90. doi: 10.3969/j.issn.1006-0111.201906097
Effects of ziprasidone on serum cholinesterase concentration in schizophrenia patients
Department of Pharmacy, Jiaxing Kangci Hospital, Jiaxing 314500, China
2.
Clinical Laboratory, Jiaxing Kangci Hospital, Jiaxing 314500, China
Received Date: 2019-06-27
Rev Recd Date:
2019-10-31
Abstract
Objective To explore the effects of ziprasidone and clozapine on serum cholinesterase (CHE) concentration in schizophrenia patients. Methods 126 schizophrenia patients were randomly divided into the observation group and the control group. The observation group was treated with ziprasidone. The control group received clozapine. The serum CHE concentration was assayed at 7, 14 and 28 days after treatment. Results ① The PANSS scores in both groups were significantly reduced after treatment, while the control group was lower than the observation group (PANSS score for positive symptoms:15.3±4.7 vs 22.4±4.8, P<0.01; negative symptoms:14.6±4.5 vs 21.8±5.2, P<0.01; general psychiatric symptoms:13.3±3.4 vs 19.2±3.9, P<0.01). ② CHE levels were decreased in both groups after treatment. The control group exhibited greater decrease than the observation group. ③ The observation group had lower adverse reaction rate (34.9%) compared to control group (71.4%). Conclusion ziprasidone has weaker inhibitory effect on CHE activity compared to clozapine. This may explain that ziprasidone has lower therapeutic efficacy and better safety profile.
Abstract: Objective To explore the effects of ziprasidone and clozapine on serum cholinesterase (CHE) concentration in schizophrenia patients. Methods 126 schizophrenia patients were randomly divided into the observation group and the control group. The observation group was treated with ziprasidone. The control group received clozapine. The serum CHE concentration was assayed at 7, 14 and 28 days after treatment. Results ① The PANSS scores in both groups were significantly reduced after treatment, while the control group was lower than the observation group (PANSS score for positive symptoms:15.3±4.7 vs 22.4±4.8, P<0.01; negative symptoms:14.6±4.5 vs 21.8±5.2, P<0.01; general psychiatric symptoms:13.3±3.4 vs 19.2±3.9, P<0.01). ② CHE levels were decreased in both groups after treatment. The control group exhibited greater decrease than the observation group. ③ The observation group had lower adverse reaction rate (34.9%) compared to control group (71.4%). Conclusion ziprasidone has weaker inhibitory effect on CHE activity compared to clozapine. This may explain that ziprasidone has lower therapeutic efficacy and better safety profile.
LIU Yayi, ZHANG Junping. Research progress of cryptotanshinone on anti-fibrosis and its mechanism[J]. Journal of Pharmaceutical Practice and Service, 2023, 41(3): 146-148, 186. doi: 10.12206/j.issn.2097-2024.202208061
Citation:
FANG Huiyu, GU Yanying. Effects of ziprasidone on serum cholinesterase concentration in schizophrenia patients[J]. Journal of Pharmaceutical Practice and Service, 2020, 38(1): 88-90. doi: 10.3969/j.issn.1006-0111.201906097
LIU Yayi, ZHANG Junping. Research progress of cryptotanshinone on anti-fibrosis and its mechanism[J]. Journal of Pharmaceutical Practice and Service, 2023, 41(3): 146-148, 186. doi: 10.12206/j.issn.2097-2024.202208061
LIU Yayi, ZHANG Junping. Research progress of cryptotanshinone on anti-fibrosis and its mechanism[J]. Journal of Pharmaceutical Practice and Service, 2023, 41(3): 146-148, 186. doi: 10.12206/j.issn.2097-2024.202208061